31 March 2017

MaxCyte, Inc.

MaxCyte, Inc. (LSE: MXCT), a US-based company dedicated to driving commercialisation of next-generation, cell-based medicines, announced an equity placing that raised gross proceeds of £20 million. 

The funding will be used to further the company's programme for Ovarian Cancer and Acute Myeloid Leukemia through its IND application and into clinical studies; and to expand into new indications by financing pre-clinical and IND enabling studies in advance of possible clinical studies.  LGB Investments worked with the company's broker, Panmure Gordon, to expand distribution of the issue.

Recent Articles

26 May 2020

BoE: Negative interest rates not ruled out

Andrew Boyle, CEO of LGB & Co. Limited, contributed to an article for Mortgage Introducer Bank of England Governor Andrew Bailey's refusal to rule out the prospect of negative interest rates.

 

Read more

News & Insights

4 May 2020

Small cap movers: Coronavirus crisis shines a light on small-cap pharma

Ivan Sedgwick, Investments Director at LGB & Co. Limited, contributed to an article for ProActive Investors on small-cap pharmaceutical companies in the Coronavirus limelight.

Read more

News & Insights

30 April 2020

What impact is COVID-19 having on stocks?

Ivan Sedgwick, Director of Investments at LGB & Co, spoke to BLM to find out about the current outlook for the AIM market.

 

Read more

News & Insights